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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Georgian language. 
The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (26% systemic, 57% oligoarticular, 16% RF negative polyarthritis, and 1% 
RF positive polyarthritis) and 100 healthy children, were enrolled at two paediatric rheumatology centre. Notably, none of the 
enrolled JIA patients is affected with psoriatic arthritis or with enthesitis-related arthritis or with undifferentiated arthritis. 
The JAMAR components discriminated healthy subjects from JIA patients, except for the school-related problems variable. 
All JAMAR components revealed good psychometric performances. In conclusion, the Georgian version of the JAMAR is a 
valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Georgian parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
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reported outcomes in JIA, including overall well-being, 
functional status, health related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Georgian language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from October 2012 
to January2014. Children were recruited after Ethics Com-
mittee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15-items in 
which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated. [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of 
the illness (Yes/No) [15].The JAMAR is available in 
three versions, one for parent proxy-report (child’s age 
2–18), one for child self-report, with the suggested age 
range of 7–18 years, and one for adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-culturally adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Lik-
ert assumption [mean and standard deviation (SD) equiva-
lence]; the second Likert assumption or equal items–scale 
correlations (Pearson r: all items within a scale should con-
tribute equally to the total score); third Likert assumption 
(item internal consistency or linearity for which each item 
of a scale should be linearly related to the total score that is 
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90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the 6 JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].Quantitative data were reported as medians 
with 1st and 3rd quartiles and categorical data as absolute 
frequencies and percentages.
The complete Georgian parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross cultural adaptation
The Georgian JAMAR was fully cross-culturally adapted 
with 2 forward and 2 backward translations with a concord-
ance for 110/123 translations lines (89.4%) for the parent 
version and 106/120 lines (88.3%) for the child version.
In the probe technique analysis, 118/123 (96%) lines of 
the parent version of the JAMAR were understood by at 
least 80% of the 10 parents tested (median = 100%; range: 
50–100%) and113/120 (94%) lines of the patient version of 
the JAMAR were understood by at least 80% of the children 
(median = 100%; range: 70–100%). Lines 45, 70, 79, 90, and 
105 of the parent JAMAR and 24, 45, 51, 58, 77, 86, and 106 
were modified according to parents and patients indications, 
respectively.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total 
of 200 subjects), were enrolled at two paediatric rheumatol-
ogy centres.
In the 100 JIA subjects, the JIA categories were 26% with 
systemic arthritis, 57% with oligoarthritis, 16% with RF neg-
ative polyarthritis and 1.0% with RF positive polyarthritis. 
Notably, none of the enrolled JIA patients is affected with 
psoriatic arthritis or with enthesitis-related arthritis or with 
undifferentiated arthritis (Table 1).
All the 200 subjects had the parent version of the JAMAR 
completed by a parent (100 from parents of JIA patients 
and 100 from parents of healthy children). The JAMAR was 
completed by 180/200 (90.0%) mothers and 20/200 (10.0%) 
fathers. The child version of the JAMAR was completed by 
103/200 (51.5%) children aged 7.3 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers. However, there was no 
significant difference between healthy subjects and their 
affected peers in the school-related item.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items, 
whereas a reduced number of response choices was used for 
the PF items 7, 12 and 15.
The mean ± SD of the items within a scale were roughly 
equivalent for the PF (data not shown). The median number 
of items marked as not applicable was 0% (0–0%) for the PF 
and 0% (0–4.0%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 86.0% (64–91%) for the PF 
items, 57% (46–60%) for the HRQoL PhH items, and 51% 
(49–55%) for the HRQoL PsH items. The median ceiling 
effect was 2% (1–7%) for the PF items, 10% (7–12%) for 
the HRQoL PhH items, and 3% (2–4%) for the HRQoL PsH 
items. The median floor effect was 46% for the pain VAS, 
44% for the disease activity VAS and 37% for the well-being 
VAS. The median ceiling effect was 2% for the pain VAS, 
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3% for the disease activity VAS and 2% for the well-being 
VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 80% of the PF 
items, with the exception of PF items 9, 11 and 15, and for 
100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 11 and 15) and 100% of items 
of the HRQoL.
Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refers to the 100 JIA patients and to the 100 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF− Poly-arthritis RF + Poly-arthritis All JIA patients Healthy
N = 26 N = 57 N = 16 N = 1 N = 100 N = 100
Female 13 (50%) 38 (66.7%) 12 (75%) 1 (100%) 64 (64%) 50 (50%)*
Age at visit 11.6 (4.6–13.6) 6.2 (4–10.1) 11.6 (6.4–15) 14 (14–14) 8.1 (4.4–12.7)* 9.4 (7.7–13.2)*
Age at onset 6.1 (2.4–11.2) 3.1 (1.6–5.5) 5.3 (2.7–8.6) 13.3 (13.3–13.3) 3.8 (2–8)*
Disease duration 2.5 (1-4.9) 2 (0.7–4.6) 4.6 (2.5–8.5) 0.7 (0.7–0.7) 2.6 (0.9–5.2)
ESR 9.5 (5–18) 13 (7–20) 11 (6.5–19.5) 15 (15–15) 11 (7–20)
MD VAS (0–10 cm) 0 (0-4.5) 4 (0–6) 2.5 (0-5.5) 4 (4–4) 3.3 (0-5.8)
No. swollen joints 0 (0–2) 1 (0–2) 0 (0–1.5) 5 (5–5) 0 (0–2)
No. of joints with pain 0 (0–2) 1 (0–2) 0.5 (0–3) 5 (5–5) 0.5 (0–2)
No. of joints with LOM 0 (0–2) 1 (0–2) 2.5 (1-16.5) 5 (5–5) 1 (0–2)**
No. of active joints 0 (0–2) 1 (0–2) 1.5 (0–3) 5 (5–5) 1 (0–2)
Active systemic features 2 (7.7%) 0 (0%) 0 (0%) 0 (0%) 2 (2%)
ANA status 0 (0%) 5 (8.8%) 1 (6.3%) 0 (0%) 6 (6%)
Uveitis 1 (3.8%) 5 (10.6%) 1 (6.7%) 0 (0%) 7 (7.9%)
PF Total Score 0 (0–3) 3 (0–6) 4.5 (2–11) 2 (2–2) 2 (0–6)* 0 (0–0)#
Pain VAS 0 (0–3) 3 (0–5) 0.3 (0-3.3) 1.5 (1.5–1.5) 1 (0–5) 0 (0–0)#
Disease Activity VAS 0 (0-4.5) 4 (0–6) 2 (0-4.5) 1.5 (1.5–1.5) 2 (0–6)
Well-being VAS 0 (0–5) 4 (0–6) 3.5 (0.3–4.8) 3 (3–3) 2.8 (0–6)
HRQoL PhH 0 (0–2) 2 (1–6) 2 (0-4.5) 1 (1–1) 2 (0–6) 0 (0–0)#
HRQoL PsH 2 (0–6) 1 (0–5) 2 (0.5–4.5) 1 (1–1) 2 (0–5) 0 (0–0)#
HRQoL Total Score 2.5 (0–7) 4 (2–13) 4 (0.5-9) 2 (2–2) 4 (1–11) 0 (0–1)#
Pain/swell. in > 1 joint 8 (30.8%) 36 (63.2%) 8 (50%) 1 (100%) 53 (53%) 1 (1%)#
Morning stiffness > 15 min 5 (19.2%) 26 (45.6%) 3 (18.8%) 0 (0%) 34 (34%) 0 (0%)#
Subjective remission 9 (34.6%) 38 (66.7%) 10 (62.5%) 1 (100%) 58 (58%)*
In treatment 18 (69.2%) 24 (42.1%) 11 (68.8%) 1 (100%) 54 (54%)
Reporting side effects 13/18 (72.2%) 7/24 (29.2%) 3/11 (27.3%) 0 (0%) 23/54 (42.6%)*
Taking medication regularly 17/18 (94.4%) 23/24 (95.8%) 11/11 (100%) 1 (100%) 52/54 (96.3%)
With problems attending school 0 (0%) 5/29 (17.2%) 0 (0%) 0 (0%) 5/50 (10%) 2 (2.9%)
Satisfied with disease outcome 19 (73.1%) 23 (40.4%) 10 (62.5%) 1 (100%) 53 (53%)
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.98 for PF-LL, 0.89 for PF-HW, 
0.79 for PF-US. Cronbach’s alpha was 0.94 for HRQoL-
PhH and 0.91 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent N = 100/200 Child N = 30/103
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 86.0% 76.7%
 HRQoL PhH 57.0% 66.7%
 HRQoL PsH 51.0% 73.3%
 Pain VAS 46.0% 60.0%
 Disease activity VAS 44.0% 60.0%
 Well-being VAS 37.0% 56.7%
Ceiling effect, median
 PF 2.0% 0.0%
 HRQoL PhH 10.0% 6.7%
 HRQoL PsH 3.0% 3.3%
 Pain VAS 2.0% 3.3%
 Disease activity VAS 3.0% 3.3%
 Well-being VAS 2.0% 3.3%
Items with equivalent item–scale correlation 80% for PF, 100% for HRQoL 87% for PF, 90% for HRQoL
Items with items–scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.98 0.98
 PF-HW 0.89 0.92
 PF-US 0.79 0.84
 HRQoL-PhH 0.94 0.95
 HRQoL-PsH 0.91 0.88
Items with item–scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.87 0.96
 HRQoL-PhH 0.73 1.0
 HRQoL-PsH 0.74 0.77
Spearman correlation with JIA core-set variables, median
 PF 0.8 0.8
 HRQoL PhH 0.8 0.9
 HRQoL PsH 0.7 0.8
 Pain VAS 0.7 0.8
 Disease activity VAS 0.8 0.9
 Well-being VAS 0.8 0.8
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Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-admin-
istering both versions (parent and child) of the JAMAR 
after a median of 5.5 days (0–6 days). The intraclass cor-
relation coefficients (ICC) for the PF total score showed an 
almost perfect reproducibility (ICC = 0.87). The ICC for the 
HRQoL PhH and for the HRQoL PsH showed a substantial 
reproducibility (ICC = 0.73 and ICC = 0.74, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.7 to 0.8 
(median = 0.8). The PF total score best correlation was 
observed with the parent’s assessment of well-being (r = 0.8, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.6 to 0.9 (median = 0.8), whereas for the PsH ranged from 
0.6 to 0.7 (median = 0.7). The PhH showed the best correla-
tion with the parent’s assessment of pain (r = 0.9, p < 0.001) 
and the PsH showed the best correlation with the parent’s 
assessment of well-being (r = 0.7, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centred and 
laboratory measures were 0.7 (0.6–0.8), 0.8 (0.7–0.9), 0.8 
(0.7–0.9), respectively.
Discussion
In this study, the Georgian version of the JAMAR was cross-
culturally adapted from the original standard English version 
with 2 forward and 2 backward translations. According to 
the results of the validation analysis, the Georgian parent 
and patient versions of the JAMAR possess satisfactory psy-
chometric properties. The disease-specific components of 
the questionnaire discriminated well between patients with 
JIA and healthy controls. Notably, there was no significant 
difference between the healthy subjects and their affected 
peers in the school-related problems. These findings indi-
cates that children with JIA adapt well to the consequences 
of JIA, and have school performances comparable to those 
of their healthy peers. The functional ability questionnaire 
PF revealed to be able to discriminate between the different 
JIA subtypes with the children diagnosed with RF-negative 
polyarthritis having a higher degree of disability.
Psychometric evaluation was good for all domains with 
few exceptions: 2 PF items (stretch out arms and bite a sand-
wich or an apple) showing a lower Items internal consist-
ency. However, the overall internal consistency was excellent 
for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from strong to very strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Georgian version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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